We collaborate with global biotech/biopharma to jointly develop first- or best-in-class* innovative products and build a pharmaceutical ecosystem in a collaborative setting for the benefit of all stakeholders, whilst improving pharmaceutical R&D efficiency by accelerating the time to approval and increasing the likelihood of success.
We have a well-invested infrastructure and experienced teams to control key stages of the entire product life cycle, an extensive expert network covering various specialty fields, deep market understanding and a strong financial footing. Leveraging the above strengths, we are able to identify unmet clinical needs, as well as efficiently promote the clinical development and commercialization of innovative products. This continuing translation of scientific research into clinical practices has benefited patients over multiple decades and remains a core ambition.
We deeply expertise in several therapeutic fields, including cardio-cerebrovascular, gastrointestinal, central nervous system, dermatology and medical aesthetics, ophthalmology and pediatrics etc. In many cases we have proven our ability to take a product and grow it into a market leading position which is evidenced by our over 20% CAGRs of net profit and revenue over the past 15 years (2008-2022).
Each of these therapeutic areas is formed as an independent division, with a dedicated team and integrated resources in specialty fields, whilst being able to access and benefit from the central functions. This gives the advantages of an entrepreneurial focus of growth whilst allowing the divisions to benefit from the scale advantages and operational efficiency inherent with being part of a larger group. We believe this operation structure will empower the divisions to gain leading positions in specialty markets. At the same time, we have entered the Southeast Asian market to expand our business territory to create new driving force, further escorting the sustainable and healthy development of the Group.
*Best-in-class: innovative products with the best efficacy, safety or cost-effectiveness in the class due to their innovative formulations or drug delivery systems
Revenue
（In the case that all medicines were directly sold by the Group）
Net profit
Innovative Pipeline Products
Employees
Chinese hospitals/medical institutions covered in sales network
Chinese drugstores covered in sales network
*As at 31 December 2022
Value Creation for Customers
Innovation
Integrity
Pragmatism
Perseverance
Win-win
